Restore Mind Medicine

What ISS Left Completely Out Source: Company SEC Filings X X X X The Board has entrenched management with golden parachutes. The Board approved the MM-110 dosing without proper safety data, and the flawed, unnecessary Phase llb. The Board's lack of alignment with shareholders owning just .22% of outstanding MindMed shares v. FCM's 3.5% beneficial ownership. Our pledge to lock up our shares until June 15, 2026, demonstrating alignment with shareholders. The numerous unfulfilled promises that MindMed has made including purported partnerships in digital medicine and Phase II trials. There are no shareholder voices in the boardroom who are willing or capable to hold management to account. 13

View entire presentation